Centene reports Q4 net loss attributable to shareholders of USD 1.10 billion

Reuters
02/06
Centene reports Q4 net loss attributable to shareholders of USD 1.10 billion

Centene Corporation reported a net loss attributable to the company of USD -1.10 billion for the period. Basic and diluted earnings per common share were both USD -2.24. The weighted average number of common shares outstanding was 491.53 million for basic and diluted calculations. The company noted the impact of state-directed payments, which are recorded as premium revenue and medical costs at close to a 100 percent health benefits ratio. Pass-through payments, defined as non-risk supplemental payments from states that Centene is required to transfer to designated contracted providers, are recorded as premium tax revenue and premium tax expense. Centene reaffirmed its commitment to providing fully integrated, high-quality, and cost-effective services to government-sponsored healthcare programs, emphasizing its local approach with local brands and teams. The company also highlighted that its forward-looking statements, including its 2026 full year guidance, are covered by the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Centene Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: CG82208) on February 06, 2026, and is solely responsible for the information contained therein.

應版權方要求,你需要登入查看該內容

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10